Page 67 - Read Online

Tn-positive invasive bladder cancer xenografts in nude mice: an Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E,
exploratory model study. Anticancer Res 2014;34:735-44. Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill
21. Ferreira JA, Videira PA, Lima L, Pereira S, Silva M, Carrascal L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G,
M, Severino PF, Fernandes E, Almeida A, Costa C, Vitorino R, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan
Amaro T, Oliveira MJ, Reis CA, Dall’Olio F, Amado F, Santos LL. P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR,
Overexpression of tumour-associated carbohydrate antigen sialyl-Tn Schlegel R, Garraway LA. Genomic characterization of three urinary
in advanced bladder tumours. Mol Oncol 2013;7:719-31. bladder cancer cell lines: understanding genomic types of urinary
22. Hoffman RM. Patient-derived orthotopic xenografts: better mimic bladder cancer. Tumour Biol 2014;35:4599-617.
of metastasis than subcutaneous xenografts. Nat Rev Cancer 32. Ching CB, Hansel DE. Expanding therapeutic targets in bladder
2015;15:451-2. cancer: the PI3K/Akt/mTOR pathway. Lab Invest 2010;90:1406-14.
23. Yang L, Carbone DP. Tumor-host immune interactions and dendritic 33. Netto GJ, Cheng L. Emerging critical role of molecular
cell dysfunction. Adv Cancer Res 2004;92:13-27. testing in diagnostic genitourinary pathology. Arch Pathol Lab
24. Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson Med2012;136:372-90.
S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli 34. Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell
L, Li E, Collins C, Wang Y, Black PC. Patient-derived bladder cancer carcinoma. Cancer Treat Rev 2013;39:709-19.
xenografts in the preclinical development of novel targeted therapies. 35. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR
Oncotarget 2015;6:21522-32. pathway: a new target in cancer therapy. Curr Cancer Drug Targets
25. Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English 2010;10:484-95.
J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ. 36. Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R,
Establishment in severe combined immunodeficiency mice of subrenal Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A,
capsule xenografts and transplantable tumor lines from a variety of Guedes-Teixeira CI, Colaço A, Palomino LF, Lopes C, Santos
primary human lung cancers: potential models for studying tumor L, Oliveira PA. In vivo and in vitro effects of RAD001 on bladder
progression-related changes. Clin Cancer Res 2006;12:4043-54. cancer. Urol Oncol 2013;31:1212-21.
26. Lee CH, Xue H, Sutcliffe M, Sutcliffe M, Gout PW, Huntsman DG, 37. Pinto-Leite R, Botelho P, Ribeiro E, Oliveira PA, Santos L. Effect of
Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule sirolimus on urinary bladder cancer T24 cell line. J Exp Clin Cancer
xenografts of primary human ovarian tumors in SCID mice: potential Res 2009;28:3.
models. Gynecol Oncol 2005;96:48-55. 38. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen
27. Pan C, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, R, Frost P, Gibbons JJ, Wu H, Sawyers CL. Enhanced sensitivity
Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl
Development and characterization of bladder cancer patient-derived Acad Sci U S A 2001;98:10314-9.
xenografts for molecularly guided targeted therapy. PLoS One 39. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O.
2015;10:e0134346. PTEN deficiency is associated with reduced sensitivity to mTOR
28. Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, Jeon SS, inhibitor in human bladder cancer through the unhampered feedback
Lee HM, Choi HY, Lee KS. Development and characterization of a loop driving PI3K/Akt activation. Br J Cancer 2013;109:1586-92.
bladder cancer xenograft model using patient-derived tumor tissue. 40. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Colaço B, Lopes C,
Cancer Sci 2013;104:1-8. Colaço A, Costa C, da Silva VM, Oliveira P, Santos L. Everolimus
29. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, combined with cisplatin has a potential role in treatment of urothelial
Hose C, Langley J, Cronise P, Vaigro-Wolff A. Feasibility of a high- bladder cancer. Biomed Pharmacother 2013;67:116-21.
flux anticancer drug screen using a diverse panel of cultured human 41. Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Gaivão I,
tumor cell lines. J Natl Cancer Inst 1991;83:757-66. Cardoso ML, Colaço A, Santos L, Oliveira P. Everolimus enhances
30. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, gemcitabine-induced cytotoxicity in bladder-cancer cell lines. J
Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu Toxicol Environ Heal Part A 2012;75:788-99.
M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa 42. Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Palmeira C, Colaço
A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, A, Moreira da Silva V, Oliveira P, Lara Santos L. Temsirolimus
Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva improves cytotoxic efficacy of cisplatin and gemcitabine against
M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, urinary bladder cancer cell lines. Urol Oncol Semin Orig Investig
Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler 2014;32:41.e11-22.
W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan 43. Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Palmeira C, Oliveira
V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, PA, Santos L. Treatment of muscle invasive urinary bladders tumors:
Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, a potential role of the mTOR inhibitors. Biomed Aging Pathol
Garraway LA. The cancer cell line encyclopedia enables predictive 2014;4:169-78.
modelling of anticancer drug sensitivity. Nature 2012;483:603-7. 44. Chan E, Patel A, Heston W, Larchian W. Mouse orthotopic models
31. Pinto-Leite R, Carreira I, Melo J, Venkatesan K, Margolin AA, Kim for bladder cancer research. BJU Int 2009;104:1286-91.
S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, 45. Jager W, Moskalev I, Janssen C, Hayashi T, Awrey S, Gust KM, So AI,
Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa Zhang K, Fazli L, Li E, Thüroff JW, Lange D, Black PC. Ultrasound-
A, Jané-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman guided intramural inoculation of orthotopic bladder cancer xenografts:
P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de a novel high-precision approach. PLoS One 2013;8:e59536.

Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ Issue 2 ¦ February 29, 2016 ¦ 57